Product Name :
c-PLA2 (N499) polyclonal antibody Background :
Phospholipase A2s (PLA2s) constitute a family of esterases that hydrolyze the sn-2-acyl ester bond in glycerophospholipid molecules. These enzymes are generally calcium-dependent and have been found both intra- and extracellularly. By hydrolyzing the sn-2 bond in glycerophospholipids, PLA2s release fatty acids. One such fatty acid, arachidonic acid, generates the substrates for the initiation of the arachidonic acid cascade that produces various eicosanoids (i.e. prostaglandins, leukotrienes and thromboxanes), many of which are potent mediators of inflammation. PLA2s include both the relatively low molecular weight type I and type II enzymes and the form known as cytoplasmic PLA2 (cPLA2). cPLA2 is present in the cytosol of various cells and tissues including platelets, macrophages and monoblasts; and preferentially hydrolyzes the sn-2 position of phospholipid molecules, releasing free arachidonate. Product :
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
c-PLA2 (N499) polyclonal antibody detects endogenous levels of c-PLA2 protein. Immunogen :
Synthetic peptide, corresponding to amino acids 480-530 of Human c-PLA2. Conjugate :
Unconjugated Modification :
Unmodification
c-PLA2 (N499) polyclonal antibody Background :
Phospholipase A2s (PLA2s) constitute a family of esterases that hydrolyze the sn-2-acyl ester bond in glycerophospholipid molecules. These enzymes are generally calcium-dependent and have been found both intra- and extracellularly. By hydrolyzing the sn-2 bond in glycerophospholipids, PLA2s release fatty acids. One such fatty acid, arachidonic acid, generates the substrates for the initiation of the arachidonic acid cascade that produces various eicosanoids (i.e. prostaglandins, leukotrienes and thromboxanes), many of which are potent mediators of inflammation. PLA2s include both the relatively low molecular weight type I and type II enzymes and the form known as cytoplasmic PLA2 (cPLA2). cPLA2 is present in the cytosol of various cells and tissues including platelets, macrophages and monoblasts; and preferentially hydrolyzes the sn-2 position of phospholipid molecules, releasing free arachidonate. Product :
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
c-PLA2 (N499) polyclonal antibody detects endogenous levels of c-PLA2 protein. Immunogen :
Synthetic peptide, corresponding to amino acids 480-530 of Human c-PLA2. Conjugate :
Unconjugated Modification :
Unmodification
-
Western blot (WB) analysis of c-PLA2 (N499) pAb at 1:500 dilution Lane1:THP-1 whole cell lysate(40ug) Lane2:MEF whole cell lysate(10ug) Lane3:H9C2 whole cell lysate(40ug) Lane4:K562 whole cell lysate(10ug) Lane5:Jurkat whole cell lysate(40ug)
-
Immunohistochemistry (IHC) analyzes of c-PLA2 (N499) pAb in paraffin-embedded human breast carcinoma tissue at 1:100.
Regulated Hypoxia/Reperfusion-Dependent Modulation of ERK1/2, cPLA(2), and Bcl-2/Bax : A Potential Mechanism of Neuroprotective Effect of Penehyclidine Hydrochloride
PMCID: Pubmed No.:21545309
The protective role of oxymatrine on neuronal cell apoptosis in the hemorrhagic rat brain
PMCID: Pubmed No.:22750437
Diosgenin inhibits superoxide generation in FMLP-activated mouse neutrophils via multiple pathways
PMCID: Pubmed No.:25246240
Corticotrophin-releasing factor participates in S1PR3-dependent cPLA2 expression and cell motility in vascular smooth muscle cells
PMCID: Pubmed No.:25869501
Ruscogenin suppresses mouse neutrophil activation: Involvement of protein kinase A pathway
PMCID: Pubmed No.:26134424
Diosgenin inhibits superoxide generation in FMLP-activated mouse neutrophils via multiple pathways
PMCID: Pubmed No.:25246240
Ruscogenin suppresses mouse neutrophil activation: Involvement of protein kinase A pathway
PMCID: Pubmed No.:26134424
Corticotrophin-releasing factor participates in S1PR3-dependent cPLA2 expression and cell motility in vascular smooth muscle cells
PMCID: Pubmed No.:25869501
UCN enhances TGF-beta-mediated mitoinhibition of VSMCs via counteracting TGF-beta-induced cPLA2 expression and activation
PMCID: Pubmed No.:27702653
Urocortin participates in LPS-induced apoptosis of THP-1 macrophages via S1P-cPLA2 signaling pathway
PMCID: Pubmed No.:32949605
Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.
Price/Size :
USD 368/1mg/vial
Tips:
For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).Describe :
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.Formula:
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.
Storage:
The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C.
Note :
This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.